10x Genomics Q4 revenue up 9% to $156.2M; FY net loss triples to $166M, guides FY23 rev $580-600M

10x Genomics, Inc.

2022-FY EPS reported -$1.46 revenue$516,409,000

Q4 2022 revenue $156.2M (+9% YoY); FY 2022 revenue $516.4M (+5% YoY).
Gross margin fell to 76% in Q4 (from 81%) and 77% for FY (from 85%) due to product mix.
Operating loss widened to $23.1M in Q4 and $167.9M for FY, driven by higher stock-based compensation.
Net loss for FY 2022 was $166.0M vs $58.2M in 2021; cash + securities $430M.
FY 2023 revenue guidance $580M-$600M (12-16% growth); began shipping Xenium in situ platform.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

10x Genomics, Inc. reported fourth quarter and full year ended December 31, 2022 results: revenue $156.2 million for the fourth quarter and $516.4 million for the full year, net income Net loss was $17.2 million for the fourth quarter...Net loss was $166.0 million for full year 2022. Guidance initiated.

Period: fourth quarter and full year ended December 31, 2022
Revenue: $156.2 million for the fourth quarter and $516.4 million for the full year
Net income: Net loss was $17.2 million for the fourth quarter...Net loss was $166.0 million for full year 2022
Guidance: initiated
Result: reported results

Exact text from the filing

Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided outlook for 2023. Recent Highlights • Revenue was $156.2 million for the fourth quarter and $516.4 million for the full year of 2022, representing 9% and 5% increases over the corresponding periods of 2021. • Increased cumulative instruments

View on SEC.gov

Browse all earnings releases →

10x Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001770787-23-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.